These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 2451551)

  • 1. German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy.
    Gerhartz HH; Thiel E; Brittinger G; Dörken B; Engelhard M; Engert W; Enne W; Fuchs R; Hagen-Aukamp CH; Huhn D
    Blut; 1988 Mar; 56(3):139-42. PubMed ID: 2451551
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
    Engelhard M; Meusers P; Brittinger G; Brack N; Dornoff W; Enne W; Gassmann W; Gerhartz H; Hallek M; Heise J
    Ann Oncol; 1991 Feb; 2 Suppl 2():177-80. PubMed ID: 1710919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results].
    Siegert W; Huhn D; Neubauer A; Brittinger G; Engelhard M; Gerhartz H; Heinz R; Meusers P; Stacher A; Thiel E
    Onkologie; 1988 Feb; 11(1):30-4. PubMed ID: 2452392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
    Gerhartz HH; Wilmanns W; Brittinger G; Engelhard M; Heinz R; Huhn D; Meusers P; Siegert W; Stacher A; Thiel E
    Onkologie; 1989 Feb; 12(1):22-6. PubMed ID: 2470000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-hodgkins lymphoma.
    Mead G; Woodcock J; Young C
    Clin Evid; 2003 Jun; (9):1-21. PubMed ID: 12967352
    [No Abstract]   [Full Text] [Related]  

  • 7. Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma.
    Nowrousian MR; Meier CR; Schoetensack B; Anders C; Höffken K; Osieka R; Schmidt CG
    Acta Oncol; 1989; 28(4):495-500. PubMed ID: 2477048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.
    Coleman M; Armitage JO; Gaynor M; McDermott D; Weisenburger DD; Adler K; Beshevkin M; Silver RT; Reisman AM; Pasmantier MW
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):23-33. PubMed ID: 2456620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in chemotherapy for large cell lymphoma.
    Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.
    Engelhard M; Gerhartz H; Brittinger G; Engert A; Fuchs R; Geiseler B; Gerhartz D; Haunauske AR; Hartlapp HJ; Huhn D
    Ann Oncol; 1994; 5 Suppl 2():123-5. PubMed ID: 7515644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
    Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
    J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs].
    Gutiérrez J; Osorio G; García H; Vacarezza R; Cao C
    Rev Med Chil; 1991 Sep; 119(9):990-1000. PubMed ID: 1726958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.
    Engelhard M; Brittinger G; Huhn D; Gerhartz HH; Meusers P; Siegert W; Thiel E; Wilmanns W; Aydemir U; Bierwolf S; Griesser H; Tiemann M; Lennert K
    Blood; 1997 Apr; 89(7):2291-7. PubMed ID: 9116271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
    Hehn ST; Miller TP
    Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
    Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
    Fridrik MA; Hausmaninger H; Linkesch W; Stöger M; Sill H; Neubauer M; Seewann HL; Klocker J; Haidinger R; Schiller L; Pont J; Raudaschl G; Falk M; Radaszkiewicz T
    J Clin Oncol; 1996 Jan; 14(1):227-32. PubMed ID: 8558202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHOP versus intensive regimens in non-Hodgkin's lymphoma.
    Longo DL; DeVita VT; Young RC
    N Engl J Med; 1993 Aug; 329(8):580-1; author reply 581-2. PubMed ID: 7687747
    [No Abstract]   [Full Text] [Related]  

  • 19. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
    Young RC; Longo DL; Glatstein E; Ihde DC; Jaffe ES; DeVita VT
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):11-6. PubMed ID: 2456618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
    Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
    J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.